<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;ff=20240801141225&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;ff=20240801141225&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 01 Aug 2024 18:12:26 +0000</lastbuilddate>
<pubDate>Thu, 01 Aug 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Correction to: A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39088006/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 1:ehae501. doi: 10.1093/eurheartj/ehae501. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39088006/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39088006</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae501>10.1093/eurheartj/ehae501</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39088006</guid>
<pubDate>Thu, 01 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers</dc:title>
<dc:identifier>pmid:39088006</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae501</dc:identifier>
</item>
<item>
<title>Intracranial Atherosclerotic Disease and Incident Dementia: The ARIC Study (Atherosclerosis Risk in Communities)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39087353/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: ICAD was associated with an increased risk of incident dementia, independent of CSVD, APOE4 genotype, and cardiovascular risk factors. The increased risk of dementia was evident even among participants with low CSVD burden, a group less likely to be affected by vascular dementia, and in participants with ICAD causing only low-grade stenosis. Our results suggest that ICAD may partially mediate the effect that cardiovascular risk factors have on the brain leading to dementia. Both...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 1. doi: 10.1161/CIRCULATIONAHA.123.067003. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Studies of the neurovascular contribution to dementia have largely focused on cerebral small vessel disease (CSVD), but the role of intracranial atherosclerotic disease (ICAD) remains unknown in the general population. The objective of this study was to determine the risk of incident dementia from ICAD after adjusting for CSVD and cardiovascular risk factors in a US community-based cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We acquired brain magnetic resonance imaging examinations from 2011 through 2013 in 1980 Black and White participants in the ARIC study (Atherosclerosis Risk in Communities), a prospective cohort conducted in 4 US communities. Magnetic resonance imaging examinations included high-resolution vessel wall magnetic resonance imaging and magnetic resonance angiography to identify ICAD. Of these participants, 1590 without dementia, without missing covariates, and with adequate magnetic resonance imaging image quality were followed through 2019 for incident dementia. Associations between ICAD and incident dementia were assessed using Cox proportional hazard ratios adjusted for CSVD (characterized by white matter hyperintensities, lacunar infarctions, and microhemorrhages), APOE4 genotype, and cardiovascular risk factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The mean age (SD) of study participants was 77.4 (5.2) years. ICAD was detected in 34.6% of participants. After a median follow-up of 5.6 years, 286 participants developed dementia. Compared with participants without ICAD, the fully adjusted hazard ratios (95% CIs) for incident dementia in participants with any ICAD, with ICAD only causing stenosis ≤50%, and with ICAD causing stenosis >;50% in ≥1 vessel were 1.57 (1.17-2.11), 1.41 (1.02-1.95), and 1.94 (1.32-2.84), respectively. ICAD was associated with dementia even among participants with low white matter hyperintensities burden, a marker of CSVD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: ICAD was associated with an increased risk of incident dementia, independent of CSVD, APOE4 genotype, and cardiovascular risk factors. The increased risk of dementia was evident even among participants with low CSVD burden, a group less likely to be affected by vascular dementia, and in participants with ICAD causing only low-grade stenosis. Our results suggest that ICAD may partially mediate the effect that cardiovascular risk factors have on the brain leading to dementia. Both ICAD and CSVD must be considered to understand the vascular contributions to cognitive decline.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39087353/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39087353</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067003>10.1161/CIRCULATIONAHA.123.067003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39087353</guid>
<pubDate>Thu, 01 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Di Zhao</dc:creator>
<dc:creator>Eliseo Guallar</dc:creator>
<dc:creator>Ye Qiao</dc:creator>
<dc:creator>David S Knopman</dc:creator>
<dc:creator>Maylin Palatino</dc:creator>
<dc:creator>Rebecca F Gottesman</dc:creator>
<dc:creator>Thomas H Mosley</dc:creator>
<dc:creator>Bruce A Wasserman</dc:creator>
<dc:date>2024-08-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Intracranial Atherosclerotic Disease and Incident Dementia: The ARIC Study (Atherosclerosis Risk in Communities)</dc:title>
<dc:identifier>pmid:39087353</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067003</dc:identifier>
</item>
<item>
<title>Association of Urinary Metals With Cardiovascular Disease Incidence and All-Cause Mortality in the Multi-Ethnic Study of Atherosclerosis (MESA)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39087344/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This epidemiological study in US adults indicates that urinary metal levels are associated with increased CVD risk and mortality. These findings can inform the development of novel preventive strategies to improve cardiovascular health.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 1. doi: 10.1161/CIRCULATIONAHA.124.069414. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Exposure to metals has been associated with cardiovascular disease (CVD) end points and mortality, yet prospective evidence is limited beyond arsenic, cadmium, and lead. In this study, we assessed the prospective association of urinary metals with incident CVD and all-cause mortality in a racially diverse population of US adults from MESA (Multi-Ethnic Study of Atherosclerosis).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We included 6599 participants (mean [SD] age, 62.1 [10.2] years; 53% female) with urinary metals available at baseline (2000 to 2001) and followed through December 2019. We used Cox proportional hazards models to estimate the adjusted hazard ratio and 95% CI of CVD and all-cause mortality by baseline urinary levels of cadmium, tungsten, and uranium (nonessential metals), and cobalt, copper, and zinc (essential metals). The joint association of the 6 metals as mixture and the corresponding 10-year survival probability was calculated using Cox Elastic-Net.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During follow-up, 1162 participants developed CVD, and 1844 participants died. In models adjusted by behavioral and clinical indicators, the HR (95% CI) for incident CVD and all-cause mortality comparing the highest with the lowest quartile were, respectively: 1.25 (1.03, 1.53) and 1.68 (1.43, 1.96) for cadmium; 1.20 (1.01, 1.42) and 1.16 (1.01, 1.33) for tungsten; 1.32 (1.08, 1.62) and 1.32 (1.12, 1.56) for uranium; 1.24 (1.03, 1.48) and 1.37 (1.19, 1.58) for cobalt; 1.42 (1.18, 1.70) and 1.50 (1.29, 1.74) for copper; and 1.21 (1.01, 1.45) and 1.38 (1.20, 1.59) for zinc. A positive linear dose-response was identified for cadmium and copper with both end points. The adjusted HRs (95% CI) for an interquartile range (IQR) increase in the mixture of these 6 urinary metals and the corresponding 10-year survival probability difference (95% CI) were 1.29 (1.11, 1.56) and -1.1% (-2.0, -0.05) for incident CVD and 1.66 (1.47, 1.91) and -2.0% (-2.6, -1.5) for all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This epidemiological study in US adults indicates that urinary metal levels are associated with increased CVD risk and mortality. These findings can inform the development of novel preventive strategies to improve cardiovascular health.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39087344/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39087344</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069414>10.1161/CIRCULATIONAHA.124.069414</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39087344</guid>
<pubDate>Thu, 01 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Irene Martinez-Morata</dc:creator>
<dc:creator>Kathrin Schilling</dc:creator>
<dc:creator>Ronald A Glabonjat</dc:creator>
<dc:creator>Arce Domingo-Relloso</dc:creator>
<dc:creator>Melanie Mayer</dc:creator>
<dc:creator>Katlyn McGraw</dc:creator>
<dc:creator>Marta Galvez Fernandez</dc:creator>
<dc:creator>Tiffany Sanchez</dc:creator>
<dc:creator>Anne E Nigra</dc:creator>
<dc:creator>Joel Kaufman</dc:creator>
<dc:creator>Dhananjay Vaidya</dc:creator>
<dc:creator>Miranda R Jones</dc:creator>
<dc:creator>Michael P Bancks</dc:creator>
<dc:creator>R Graham Barr</dc:creator>
<dc:creator>Daichi Shimbo</dc:creator>
<dc:creator>Wendy S Post</dc:creator>
<dc:creator>Linda Valeri</dc:creator>
<dc:creator>Steven Shea</dc:creator>
<dc:creator>Ana Navas-Acien</dc:creator>
<dc:date>2024-08-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Association of Urinary Metals With Cardiovascular Disease Incidence and All-Cause Mortality in the Multi-Ethnic Study of Atherosclerosis (MESA)</dc:title>
<dc:identifier>pmid:39087344</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069414</dc:identifier>
</item>
<item>
<title>Abdominal Aortic Aneurysm-Attributed Mortality in the United States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39084833/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 6;84(6):595-601. doi: 10.1016/j.jacc.2024.05.047.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39084833/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39084833</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.047>10.1016/j.jacc.2024.05.047</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39084833</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Marco Zuin</dc:creator>
<dc:creator>Rahul Aggarwal</dc:creator>
<dc:creator>Behnood Bikdeli</dc:creator>
<dc:creator>Lee Kirksey</dc:creator>
<dc:creator>Mohamad A Hussain</dc:creator>
<dc:creator>Marco J Bilato</dc:creator>
<dc:creator>Claudio Bilato</dc:creator>
<dc:creator>Gregory Piazza</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Abdominal Aortic Aneurysm-Attributed Mortality in the United States</dc:title>
<dc:identifier>pmid:39084833</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.047</dc:identifier>
</item>
<item>
<title>Plasma Proteomic Biomarkers of Aortic Stenosis: A Mendelian Randomization Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39084832/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 6;84(6):592-594. doi: 10.1016/j.jacc.2024.05.046.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39084832/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39084832</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.046>10.1016/j.jacc.2024.05.046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39084832</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Ta-Yu Yang</dc:creator>
<dc:creator>Aeron M Small</dc:creator>
<dc:creator>Line Dufresne</dc:creator>
<dc:creator>Gina M Peloso</dc:creator>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:creator>James C Engert</dc:creator>
<dc:creator>George Thanassoulis</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Plasma Proteomic Biomarkers of Aortic Stenosis: A Mendelian Randomization Study</dc:title>
<dc:identifier>pmid:39084832</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.046</dc:identifier>
</item>
<item>
<title>Pericardial Diseases and Best Practices for Pericardiectomy: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39084831/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>Remarkable advances have occurred in the understanding of the pathophysiology of pericardial diseases and the role of multimodality imaging in this field. Medical therapy and surgical options for pericardial diseases have also evolved substantially. Pericardiectomy is indicated for chronic or irreversible constrictive pericarditis, refractory recurrent pericarditis despite optimal medical therapy, or partial agenesis of the pericardium with a complication (eg, herniation). A multidisciplinary...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 6;84(6):561-580. doi: 10.1016/j.jacc.2024.05.048.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Remarkable advances have occurred in the understanding of the pathophysiology of pericardial diseases and the role of multimodality imaging in this field. Medical therapy and surgical options for pericardial diseases have also evolved substantially. Pericardiectomy is indicated for chronic or irreversible constrictive pericarditis, refractory recurrent pericarditis despite optimal medical therapy, or partial agenesis of the pericardium with a complication (eg, herniation). A multidisciplinary evaluation before pericardiectomy is essential for optimal patient outcomes. Overall, given the good outcomes reported, radical pericardiectomy on cardiopulmonary bypass, if feasible, is the preferred approach. Due to patient complexity, as well as the technical aspects of the surgery, pericardiectomy should be performed at high-volume centers that have the required expertise. The current review highlights the essential features of this multidisciplinary approach from diagnosis to recovery in patients undergoing pericardiectomy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39084831/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39084831</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.048>10.1016/j.jacc.2024.05.048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39084831</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Mohamed Al-Kazaz</dc:creator>
<dc:creator>Allan L Klein</dc:creator>
<dc:creator>Jae K Oh</dc:creator>
<dc:creator>Juan A Crestanello</dc:creator>
<dc:creator>Paul C Cremer</dc:creator>
<dc:creator>Michael Z Tong</dc:creator>
<dc:creator>Marijan Koprivanac</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:creator>Ismail El-Hamamsy</dc:creator>
<dc:creator>David H Adams</dc:creator>
<dc:creator>Douglas R Johnston</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Pericardial Diseases and Best Practices for Pericardiectomy: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:39084831</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.048</dc:identifier>
</item>
<item>
<title>Inquiries Into the Mechanisms by Which GLP-1 Receptor Agonists Reduce Cardiovascular Risk in Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39084830/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 6;84(6):558-560. doi: 10.1016/j.jacc.2024.05.045.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39084830/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39084830</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.045>10.1016/j.jacc.2024.05.045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39084830</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Silvio E Inzucchi</dc:creator>
<dc:creator>Andrew E Arai</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Inquiries Into the Mechanisms by Which GLP-1 Receptor Agonists Reduce Cardiovascular Risk in Diabetes</dc:title>
<dc:identifier>pmid:39084830</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.045</dc:identifier>
</item>
<item>
<title>Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39084829/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Liraglutide treatment resulted in improved myocardial perfusion, energetics, and 6-minute walk distance in patients with T2D, whereas pioglitazone showed no effect on these parameters (Lean-DM [Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes]; NCT04657939).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 6;84(6):540-557. doi: 10.1016/j.jacc.2024.04.064.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Type 2 diabetes (T2D) is characterized by insulin resistance (IR) and dysregulated insulin secretion. Glucagon-like peptide-1 receptor agonist liraglutide promotes insulin secretion, whereas thiazolidinedione-pioglitazone decreases IR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to compare the efficacies of increasing insulin secretion vs decreasing IR strategies for improving myocardial perfusion, energetics, and function in T2D via an open-label randomized crossover trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Forty-one patients with T2D (age 63 years [95% CI: 59-68 years], 27 [66%] male, body mass index 27.8 kg/m<sup>2</sup>) [95% CI: 26.1-29.5 kg/m<sup>2</sup>)]) without cardiovascular disease were randomized to liraglutide or pioglitazone for a 16-week treatment followed by an 8-week washout and a further 16-week treatment with the second trial drug. Participants underwent rest and dobutamine stress <sup>31</sup>phosphorus magnetic resonance spectroscopy and cardiovascular magnetic resonance for measuring the myocardial energetics index phosphocreatine to adenosine triphosphate ratio, myocardial perfusion (rest, dobutamine stress myocardial blood flow, and myocardial perfusion reserve), left ventricular (LV) volumes, systolic and diastolic function (mitral in-flow E/A ratio), before and after treatment. The 6-minute walk-test was used for functional assessments.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Pioglitazone treatment resulted in significant increases in LV mass (96 g [95% CI: 68-105 g] to 105 g [95% CI: 74-115 g]; P = 0.003) and mitral-inflow E/A ratio (1.04 [95% CI: 0.62-1.21] to 1.34 [95% CI: 0.70-1.54]; P = 0.008), and a significant reduction in LV concentricity index (0.79 mg/mL [95% CI: 0.61-0.85 mg/mL] to 0.73 mg/mL [95% CI: 0.56-0.79 mg/mL]; P = 0.04). Liraglutide treatment increased stress myocardial blood flow (1.62 mL/g/min [95% CI: 1.19-1.75 mL/g/min] to 2.08 mL/g/min [95% CI: 1.57-2.24 mL/g/min]; P = 0.01) and myocardial perfusion reserve (2.40 [95% CI: 1.55-2.68] to 2.90 [95% CI: 1.83-3.18]; P = 0.01). Liraglutide treatment also significantly increased the rest (1.47 [95% CI: 1.17-1.58] to 1.94 [95% CI: 1.52-2.08]; P =0.00002) and stress phosphocreatine to adenosine triphosphate ratio (1.32 [95% CI: 1.05-1.42] to 1.58 [95% CI: 1.19-1.71]; P = 0.004) and 6-minute walk distance (488 m [95% CI: 458-518 m] to 521 m [95% CI: 481-561 m]; P = 0.009).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Liraglutide treatment resulted in improved myocardial perfusion, energetics, and 6-minute walk distance in patients with T2D, whereas pioglitazone showed no effect on these parameters (Lean-DM [Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes]; NCT04657939).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39084829/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39084829</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.064>10.1016/j.jacc.2024.04.064</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39084829</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Amrit Chowdhary</dc:creator>
<dc:creator>Sharmaine Thirunavukarasu</dc:creator>
<dc:creator>Tobin Joseph</dc:creator>
<dc:creator>Nicholas Jex</dc:creator>
<dc:creator>Sindhoora Kotha</dc:creator>
<dc:creator>Marilena Giannoudi</dc:creator>
<dc:creator>Henry Procter</dc:creator>
<dc:creator>Lizette Cash</dc:creator>
<dc:creator>Sevval Akkaya</dc:creator>
<dc:creator>David Broadbent</dc:creator>
<dc:creator>Hui Xue</dc:creator>
<dc:creator>Peter Swoboda</dc:creator>
<dc:creator>Ladislav Valkovič</dc:creator>
<dc:creator>Peter Kellman</dc:creator>
<dc:creator>Sven Plein</dc:creator>
<dc:creator>Oliver J Rider</dc:creator>
<dc:creator>Stefan Neubauer</dc:creator>
<dc:creator>John P Greenwood</dc:creator>
<dc:creator>Eylem Levelt</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes</dc:title>
<dc:identifier>pmid:39084829</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.064</dc:identifier>
</item>
<item>
<title>Patch Wearable Defibrillator: Excellent Therapy, But Patient Acceptance Is a Sticky Issue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39084828/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 6;84(6):537-539. doi: 10.1016/j.jacc.2024.06.014.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39084828/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39084828</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.014>10.1016/j.jacc.2024.06.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39084828</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Emile G Daoud</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Patch Wearable Defibrillator: Excellent Therapy, But Patient Acceptance Is a Sticky Issue</dc:title>
<dc:identifier>pmid:39084828</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.014</dc:identifier>
</item>
<item>
<title>A Patch Wearable Cardioverter-Defibrillator for Patients at Risk of Sudden Cardiac Arrest</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39084827/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The novel P-WCD is a safe and effective WCD with high patient compliance. There were no deaths due to noncompliance and a high number of successful conversions (Jewel IDE study [A Clinical Evaluation of the Jewel P-WCD in Subjects at High Risk for Sudden Cardiac Arrest]; NCT05201495).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 6;84(6):525-536. doi: 10.1016/j.jacc.2024.04.063.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: For many patients, sudden cardiac arrest (SCA) risk is elevated temporarily. Wearable cardioverter-defibrillators (WCDs) can monitor and treat SCA during these temporary periods. Traditional WCDs can be uncomfortable, require frequent maintenance, and cannot be used when showering, resulting in poor compliance and avoidable SCA deaths. The Jewel is a novel, water-resistant patch-wearable cardioverter-defibrillator (P-WCD) with a machine learning detection algorithm designed to improve compliance and protection against SCA.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aims to demonstrate the safety and clinical effectiveness of a novel P-WCD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The Jewel IDE Study, a prospective, single-arm study conducted at 30 U.S. sites, enrolled patients at SCA risk due to ventricular tachycardia/ventricular fibrillation who were not candidates for or refused an implantable defibrillator. The primary safety endpoint was &lt;15% patients with clinically significant cutaneous adverse device effects and the primary effectiveness endpoint was &lt;2 inappropriate shocks/100 patient-months. Secondary endpoints were ≥1 successful ventricular tachycardia/ventricular fibrillation conversion and wear time compliance of >;14.1 h/d.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 305 patients (mean age: 57.9 years; 30.2% female, 27.9% non-White) were enrolled, of which 290 had available device data. The clinically significant cutaneous adverse device effect rate was 2.30% (upper 1-sided 98% CI: 4.80); none were severe. No device-related deaths or serious adverse events were reported. The inappropriate shock rate was 0.36/100 patient-months (upper 1-sided 98% CI: 1.53). Of 11 shocks in 9 patients, 9 shocks were adjudicated to be appropriate. Eight of 9 shocks were successful with a single shock. Median wear time compliance was 23.5 (20.7-23.9) h/d.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The novel P-WCD is a safe and effective WCD with high patient compliance. There were no deaths due to noncompliance and a high number of successful conversions (Jewel IDE study [A Clinical Evaluation of the Jewel P-WCD in Subjects at High Risk for Sudden Cardiac Arrest]; NCT05201495).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39084827/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39084827</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.063>10.1016/j.jacc.2024.04.063</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39084827</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>John Hummel</dc:creator>
<dc:creator>Mahmoud Houmsse</dc:creator>
<dc:creator>Gery Tomassoni</dc:creator>
<dc:creator>Devi Nair</dc:creator>
<dc:creator>Jorge Romero</dc:creator>
<dc:creator>Joe Hargrove</dc:creator>
<dc:creator>Kiran Mathews</dc:creator>
<dc:creator>Anjali B Thakkar</dc:creator>
<dc:creator>Steven Ullery</dc:creator>
<dc:creator>Zubin J Eapen</dc:creator>
<dc:creator>Uday N Kumar</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Jewel IDE Study Investigators</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A Patch Wearable Cardioverter-Defibrillator for Patients at Risk of Sudden Cardiac Arrest</dc:title>
<dc:identifier>pmid:39084827</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.063</dc:identifier>
</item>
<item>
<title>Shining a New Light Into the Black Box: From Reserve to Resistance, to Resistance Reserve</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39084826/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 6;84(6):522-524. doi: 10.1016/j.jacc.2024.06.007.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39084826/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39084826</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.007>10.1016/j.jacc.2024.06.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39084826</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Tim P van de Hoef</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Shining a New Light Into the Black Box: From Reserve to Resistance, to Resistance Reserve</dc:title>
<dc:identifier>pmid:39084826</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.007</dc:identifier>
</item>
<item>
<title>Intervention in School-Aged Children to Prevent Progression of Obesity and Cardiometabolic Disease: A Paradigm Shift Indeed</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39084825/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 6;84(6):509-511. doi: 10.1016/j.jacc.2024.06.003.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39084825/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39084825</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.003>10.1016/j.jacc.2024.06.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39084825</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Carl J Lavie</dc:creator>
<dc:creator>Ian J Neeland</dc:creator>
<dc:creator>Francisco B Ortega</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Intervention in School-Aged Children to Prevent Progression of Obesity and Cardiometabolic Disease: A Paradigm Shift Indeed</dc:title>
<dc:identifier>pmid:39084825</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.003</dc:identifier>
</item>
<item>
<title>Effect of Time-Varying Exposure to School-Based Health Promotion on Adiposity in Childhood</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39084824/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Early elementary school interventions may be more effective than later interventions on abdominal adiposity. Further research should assess the sustainability effects of school-based health promotion programs.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 6;84(6):499-508. doi: 10.1016/j.jacc.2024.04.065.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The results of most school-based health promotion initiatives are inconclusive.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This trial assessed the effect of time-varying exposures to a multicomponent school-based health promotion intervention (SI! Program) on adiposity markers.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 48 schools in Madrid (Spain) were cluster randomized to receive the SI! Program through elementary education grades 1 to 6 (E1-6, 12 schools, 459 children), 1 to 3 (E1-3, 12 schools, 513 children), or 4 to 6 (E4-6, 12 schools, 419 children) or to receive the standard curriculum (control, 12 schools, 379 children). The primary endpoint was the between-group difference at 3- and 6-year follow-up in the change from baseline in adiposity markers and the overall knowledge-attitudes-habits (KAH) score.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At 3-year follow-up, children who had the intervention showed significantly lower increases than the control group in z-scores for body mass index (BMI), waist-to-height ratio (WHtR), and waist circumference (WC) (zBMI: -0.09; 95% CI: -0.16 to -0.03; P = 0.003; zWC and zWHtR: -0.19; 95% CI: -0.28 to -0.10; P &lt; 0.001). At 6-year follow-up, the beneficial trend in zWC and zWHtR was maintained in the E1-6 and E1-3 groups: difference zWC control vs E1-6 (-0.19; 95% CI: -0.36 to -0.03; P = 0.020), control vs E1-3 (-0.22; 95% CI: -0.38 to -0.06; P = 0.009); difference zWHtR control vs E1-6 (-0.24; 95% CI: -0.41 to -0.06; P = 0.009), and control vs E1-3 (-0.29; 95% CI: -0.47 to -0.11; P = 0.001). No significant between-group differences were found in the change of overall KAH score.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Early elementary school interventions may be more effective than later interventions on abdominal adiposity. Further research should assess the sustainability effects of school-based health promotion programs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39084824/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39084824</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.065>10.1016/j.jacc.2024.04.065</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39084824</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Gloria Santos-Beneit</dc:creator>
<dc:creator>Patricia Bodega</dc:creator>
<dc:creator>Amaya de Cos-Gandoy</dc:creator>
<dc:creator>Mercedes de Miguel</dc:creator>
<dc:creator>Carla Rodríguez</dc:creator>
<dc:creator>Xavier Orrit</dc:creator>
<dc:creator>Vanesa Carral</dc:creator>
<dc:creator>Domingo Haro</dc:creator>
<dc:creator>Isabel Carvajal</dc:creator>
<dc:creator>Carlos Peyra</dc:creator>
<dc:creator>Jesús Martínez-Gómez</dc:creator>
<dc:creator>Juan Miguel Fernández-Alvira</dc:creator>
<dc:creator>Rodrigo Fernández-Jiménez</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effect of Time-Varying Exposure to School-Based Health Promotion on Adiposity in Childhood</dc:title>
<dc:identifier>pmid:39084824</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.065</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39083704/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 30;149(18):1461-1465. doi: 10.1161/CIRCULATIONAHA.124.069841. Epub 2024 Apr 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39083704/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39083704</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069841>10.1161/CIRCULATIONAHA.124.069841</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39083704</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:date>2024-07-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:39083704</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069841</dc:identifier>
</item>
<item>
<title>Factors Underlying Reduced Hospitalizations for Myocardial Infarction During the COVID-19 Pandemic</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39083317/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: The early reduction in AMI encounters was likely driven by care avoidance, while ongoing reductions through June 2023 likely reflect long-standing temporal trends. During the pandemic, there were 5% fewer AMI encounters than expected.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 31. doi: 10.1001/jamacardio.2024.2031. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The incidence of hospital encounters for acute myocardial infarction (AMI) decreased sharply early in the COVID-19 pandemic and has not returned to prepandemic levels. There has been an ongoing debate about what mechanism may underlie this decline, including patients avoiding the hospital for treatment, excess mortality from COVID-19 among patients who would otherwise have had an AMI, a reduction in the incidence or severity of AMIs due to pandemic-related changes in behavior, or a preexisting temporal trend of lower AMI incidence.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To describe drivers of changing incidence in AMI hospital encounters during the COVID-19 pandemic.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used traditional Medicare claims from all patients enrolled in traditional Medicare from January 2016 to June 2023 (total of 2.85 billion patient-months) to calculate the rate of AMI hospital encounters (emergency department visits, observation stays, or inpatient admissions) per capita at all short-term acute care and critical access hospitals in the United States overall and by patient characteristics. Observed rates were compared with expected rates that accounted for shifts in population characteristics and the prepandemic temporal trend (as estimated over 2016-2019). Data were analyzed in November 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Hospital encounters for AMI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: On average, the study sample included 31 623 928 patients each month from January 2016 through June 2023, for a total of 2 846 153 487 patient-months during the 90-month study period. In June 2023, there were 0.044 AMI hospital encounters per 100 patients, which was 20% lower than in June 2019 (0.055 encounters per 100 patients). Early in the pandemic, AMI rates moved inversely with COVID-19 death rates and tracked patterns seen for other painful acute conditions, such as nephrolithiasis, suggesting these changes were associated with care avoidance. Changes in patient characteristics driven by excess deaths during the pandemic explained little of the decline. Later in the pandemic, the decline may be explained by the long-standing downward trend in AMI incidence; by April 2022, the observed rate of encounters matched the expected rate that accounted for this trend. During the full pandemic period, from March 2020 to June 2023, there were an estimated 5% (95% prediction interval, 1%-9%) fewer AMI hospital encounters than expected.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: The early reduction in AMI encounters was likely driven by care avoidance, while ongoing reductions through June 2023 likely reflect long-standing temporal trends. During the pandemic, there were 5% fewer AMI encounters than expected.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39083317/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39083317</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2031>10.1001/jamacardio.2024.2031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39083317</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Andrew D Wilcock</dc:creator>
<dc:creator>Jose R Zubizarreta</dc:creator>
<dc:creator>Rishi K Wadhera</dc:creator>
<dc:creator>Robert W Yeh</dc:creator>
<dc:creator>Kori S Zachrison</dc:creator>
<dc:creator>Lee H Schwamm</dc:creator>
<dc:creator>Ateev Mehrotra</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Factors Underlying Reduced Hospitalizations for Myocardial Infarction During the COVID-19 Pandemic</dc:title>
<dc:identifier>pmid:39083317</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2031</dc:identifier>
</item>
<item>
<title>Heart Failure-Together We Go Farther</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39083307/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 31. doi: 10.1001/jamacardio.2024.2181. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39083307/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39083307</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2181>10.1001/jamacardio.2024.2181</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39083307</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Lorenz Van der Linden</dc:creator>
<dc:creator>Wilfried Mullens</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Heart Failure-Together We Go Farther</dc:title>
<dc:identifier>pmid:39083307</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2181</dc:identifier>
</item>
<item>
<title>Leadless Ultrasound-Based Cardiac Resynchronization Therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39083267/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 31. doi: 10.1001/jamacardio.2024.2067. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39083267/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39083267</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2067>10.1001/jamacardio.2024.2067</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39083267</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Fred M Kusumoto</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Leadless Ultrasound-Based Cardiac Resynchronization Therapy</dc:title>
<dc:identifier>pmid:39083267</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2067</dc:identifier>
</item>
<item>
<title>Acute Myocardial Infarction Admissions During the COVID-19 Peak</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39083263/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 31. doi: 10.1001/jamacardio.2024.2187. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39083263/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39083263</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2187>10.1001/jamacardio.2024.2187</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39083263</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Vinay Guduguntla</dc:creator>
<dc:creator>Robert O Bonow</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Acute Myocardial Infarction Admissions During the COVID-19 Peak</dc:title>
<dc:identifier>pmid:39083263</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2187</dc:identifier>
</item>
<item>
<title>Leadless Ultrasound-Based Cardiac Resynchronization System in Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39083254/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: The SOLVE-CRT study has demonstrated that leadless LV endocardial pacing with the WiSE CRT system is associated with a reduction in LVESV in patients with HF. This novel system may represent an alternative to conventional CRT implants in some HF patient populations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 31. doi: 10.1001/jamacardio.2024.2050. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Approximately 40% of patients with heart failure (HF) who are eligible for cardiac resynchronization therapy (CRT) either fail to respond or are untreatable due to anatomical constraints.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the safety and efficacy of a novel, leadless, left ventricular (LV) endocardial pacing system for patients at high risk for a CRT upgrade or whose coronary sinus (CS) lead placement/pacing with a conventional CRT system failed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The SOLVE-CRT study was a prospective multicenter trial, enrolling January 2018 through September 2022, with follow-up in March 2023. Data were analyzed from DATE MONTH, YEAR, through DATE MONTH, YEAR. The trial combined data from an initial randomized, double-blind study (n = 108) and a subsequent single-arm part (n = 75). It took place at 36 centers across Australia, Europe, and the US. Participants were nonresponders, previously untreatable (PU), or high-risk upgrades (HRU). All participants contributed to the safety analysis. The primary efficacy analysis (n = 100) included 75 PU-HRU patients from the single-arm part and 25 PU-HRU patients from the randomized treatment arm.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Patients were implanted with the WiSE CRT System (EBR Systems) consisting of a leadless LV endocardial pacing electrode stimulated with ultrasound energy delivered by a subcutaneously implanted transmitter and battery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary safety end point was freedom from type I complications. The primary efficacy end point was a reduction in mean LV end systolic volume (LVESV).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study included 183 participants; mean age was 68.1 (SD, 10.3) years and 141 were male (77%). The trial was terminated at an interim analysis for meeting prespecified stopping criteria. In the safety population, patients were either New York Heart Association Class II (34.6%) or III (65.4%). The primary efficacy end point was met with a 16.4% (95% CI, -21.0% to -11.7%) reduction in mean LVESV (P = .003). The primary safety end point was met with an 80.9% rate of freedom from type I complications (P &lt; .001), which included 12 study device system events (6.6%), 5 vascular events (2.7%), 3 strokes (1.6%), and 7 cardiac perforations which mostly occurred early in the study (3.8%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: The SOLVE-CRT study has demonstrated that leadless LV endocardial pacing with the WiSE CRT system is associated with a reduction in LVESV in patients with HF. This novel system may represent an alternative to conventional CRT implants in some HF patient populations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT0292203.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39083254/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39083254</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2050>10.1001/jamacardio.2024.2050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39083254</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jagmeet P Singh</dc:creator>
<dc:creator>Christopher A Rinaldi</dc:creator>
<dc:creator>Prashanthan Sanders</dc:creator>
<dc:creator>Spencer H Kubo</dc:creator>
<dc:creator>Simon James</dc:creator>
<dc:creator>Imran K Niazi</dc:creator>
<dc:creator>Timothy Betts</dc:creator>
<dc:creator>Christian Butter</dc:creator>
<dc:creator>Toshimasa Okabe</dc:creator>
<dc:creator>Ryan Cunnane</dc:creator>
<dc:creator>Emad Aziz</dc:creator>
<dc:creator>Mauro Biffi</dc:creator>
<dc:creator>Amir Zaidi</dc:creator>
<dc:creator>Jeffrey Alison</dc:creator>
<dc:creator>Pascal Defaye</dc:creator>
<dc:creator>Angelo Aurrichio</dc:creator>
<dc:creator>Michael R Gold</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:creator>Tyson Rogers</dc:creator>
<dc:creator>Mary Norine Walsh</dc:creator>
<dc:creator>SOLVE-CRT Investigators</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Leadless Ultrasound-Based Cardiac Resynchronization System in Heart Failure</dc:title>
<dc:identifier>pmid:39083254</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2050</dc:identifier>
</item>
<item>
<title>Change to Open Access Status</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39083251/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 31. doi: 10.1001/jamacardio.2024.2464. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39083251/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39083251</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2464>10.1001/jamacardio.2024.2464</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39083251</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:date>2024-07-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Change to Open Access Status</dc:title>
<dc:identifier>pmid:39083251</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2464</dc:identifier>
</item>
<item>
<title>Heart Failure-Together We Go Farther-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39083250/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240801141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 31. doi: 10.1001/jamacardio.2024.2184. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39083250/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240801141225&v=2.18.0.post9+e462414">39083250</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2184>10.1001/jamacardio.2024.2184</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39083250</guid>
<pubDate>Wed, 31 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Amber B Tang</dc:creator>
<dc:creator>Nicholas K Brownell</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:date>2024-07-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Heart Failure-Together We Go Farther-Reply</dc:title>
<dc:identifier>pmid:39083250</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2184</dc:identifier>
</item>





























</channel>
</rss>